未登录

T

Timothy Middleton

Royal Prince Alfred Hospital

H指数:15

被引数:1,059

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Pregnancy outcomes in women with young-onset type 2 diabetes: the impact of age of diabetes diagnosis and duration of diabetes

年轻发病2型糖尿病女性的妊娠结局：糖尿病诊断年龄和病程的影响

Diabetic Medicine

IF3.4

2025-05-220

OAAI

Comparing the different phenotypes of diabetes in pregnancy: Are outcomes worse for women with young-onset type 2 diabetes compared to type 1 diabetes?

DIABETES RESEARCH AND CLINICAL PRACTICE

IF7.4

2024-11-010

PRE

Improving beta-cell secretory function and glycaemia in young-onset type 2 diabetes: A pilot, 12-month, randomized trial of a novel, continuous glucose monitor-guided, rapid treatment intensification strategy incorporating empagliflozin and liraglutide

DIABETES OBESITY & METABOLISM

IF5.7

2021-12-280

PREAI

An Enhanced SMS Text Message-Based Support and Reminder Program for Young Adults With Type 2 Diabetes (TEXT2U): Randomized Controlled Trial

JOURNAL OF MEDICAL INTERNET RESEARCH

IF6

2021-10-2116

OAAI

Young-onset type 2 diabetes and younger current age: increased susceptibility to retinopathy in contrast to other complications

DIABETIC MEDICINE

IF3.4

2020-02-0531

OAAI

Does HbA1c Impact Survival in the Newly Diagnosed Elderly Aged 75 Years and Over?

IF7.5

2019-06-010

PRE

Long-Term Renal Outcomes in Young Onset Type 2 Diabetes

IF7.5

2019-06-010

PRE

In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2018-01-0169

OAAI

Cardiac Effects of Sulfonylurea-Related Hypoglycemia

IF16.6

2017-02-2131

OAAI

Complications of injectable testosterone undecanoate in routine clinical practice

EUROPEAN JOURNAL OF ENDOCRINOLOGY

IF5.2

2015-05-0129

OAAI

In Vitro and In Vivo Antiviral Activity and Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor ABT-450

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2015-02-01108

OAAI

IN VITRO COMBINATORY EFFECT OF HCV NS3/4A PROTEASE INHIBITOR ABT-450, NS5A INHIBITOR ABT-267, AND NON-NUCLEOSIDE NS5B POLYMERASE INHIBITOR ABT-333

JOURNAL OF HEPATOLOGY

IF33

2012-04-018

PREAI

FACTORS AFFECTING HCV VIRAL LOAD RESPONSE TO THE NON-NUCLEOSIDE POLYMERASE INHIBITORS ABT-072 AND ABT-333

JOURNAL OF HEPATOLOGY

IF33

2011-03-013

OAAI

RESISTANCE PROFILE OF ABT-333 AND RELATIONSHIP TO VIRAL LOAD DECREASE IN PATIENTS TREATED IN COMBINATION WITH PEG-INTERFERON AND RIBAVIRIN FOR 28 DAYS

JOURNAL OF HEPATOLOGY

IF33

2010-04-0114

OAAI

POTENT HCV PROTEASE INHIBITORS WITH THE POTENTIAL FOR ONCE-DAILY DOSING AND BROAD GENOTYPE COVERAGE

JOURNAL OF HEPATOLOGY

IF33

2009-04-012

OAAI

Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2008-03-0188

OAAI

Characterization of pharmacokinetic/pharmacodynamic parameters for the novel HCV polymerase inhibitor A-848837

JOURNAL OF HEPATOLOGY

IF33

2007-04-016

OAAI